CAI Stock Summary and Trading Ideas (Caris Life Sciences | NASDAQ:CAI)

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.

As of October 6, 2026, CAI stock price declined to $27.45 with 4,394,493 million shares trading.

CAI has a beta of 2.11, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.14 to the broad based SPY ETF.

CAI has a market cap of $7.76 billion. This is considered a Mid Cap stock.

Last quarter Caris Life Sciences reported $264 million in Revenue and $.00 earnings per share. This beat revenue expectation by $27 million and missed earnings estimates by -$.01.

The top ETF exchange traded funds that CAI belongs to (by Net Assets): VTI, VB, VBK, IBB, FXH.

CAI has underperformed the market in the last year with a price return of -13.6% while the SPY ETF gained +17.6%. However, in the short term, CAI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +50.0% vs +4.9% return in SPY. But in the last 2 weeks, CAI shares have been beat by the market, returning -10.4% compared to an SPY return of +0.7%.

CAI support price is $29.05 and resistance is $31.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.